Back

Efficiency of the use of sakubutril / valsartan on the increase in left ventricular ejection fraction in patients with coronary artery disease with HF sEFV with diabetes mellitus 2

29 June 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Clinical Trial Updates Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Raisa Trigulova

Republican Specialized Scientific Practical Medical Center Of Cardiology, Tashkent (Uzbekistan)

13 More presentations in this session

Presentation thumbnail
Omecamtiv Mecarbil in Patients with Severe Heart Failure: An Analysis from Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF)
Professor G. Felker (Durham, US)
Slides Video
Presentation thumbnail
Association of Baseline Cardiac Biomarkers on Clinical Outcomes and Vericiguat Treatment Effect in Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial
Associate Professor C. DeFilippi (Baltimore, US)
Slides Video
Presentation thumbnail
Efficacy and Safety of Antithrombotic Strategies in Patients With Atrial Fibrillation and Recent ACS or PCI With and Without A History of Heart Failure: Insights From the AUGUSTUS Trial
Doctor M. Fudim (Durham, US)
Slides Video
Presentation thumbnail
Nurse Intervention for Less Chronic Heart Failure Study
Professor S. Stewart (Fremantle, AU)
Slides Video
Presentation thumbnail
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.
Professor J. McMurray (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
Clinical Trial Updates

The Event

Event poster

Heart Failure 2021

29 June - 1 July 2021
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources